The Independent Voice of West Indies Cricket

Message Board Archives

As I said, Pfizer is a thief, Moderna is King

 
Barry 2022-08-26 13:54:28 

Link Text


Moderna said on Friday it will sue Pfizer and BioNTech for copying the “groundbreaking technology” behind its Covid-19 vaccine, setting up a legal clash between pharmaceutical rivals behind some of the best-selling jabs used to combat the pandemic.

The US biotech said it would seek damages from its rivals for allegedly infringing several patents protecting Moderna’s messenger RNA technology platform that were critical to developing its Covid jab, including one related to chemical modifications that enable mRNA to enter the human body without provoking undesirable immune responses.

Moderna said it would not strive to block the BioNTech/Pfizer vaccine from the market or seek an injunction against future sales due to the life-saving role it plays in the pandemic. The BioNTech/Pfizer vaccine is sold under the brand name Comirnaty.

But it said it expected rivals such as Pfizer and BioNTech to respect its intellectual property and would look to enforce these legal rights through lawsuits in US and German courts.

 
Halliwell 2022-08-26 15:19:36 

In reply to Barry

I eagerly await Castled’s opinions on this matter cool

 
Halliwell 2022-08-26 15:20:55 

In reply to Barry

Nobody should TOUCH litigation when it comes to COVID diagnosis, treatment or prophylaxis sad

 
Barry 2022-08-26 16:10:38 

In reply to Halliwell
Caribbean people and the diaspora do not believe in intellectual property . ..perhaps because the white man has stolen so much from you . . .

lol lol lol lol Learn to acknowledge what others have developed . . .

 
Barry 2022-08-26 16:11:19 

In reply to Halliwell

Moderna said it would not strive to block the BioNTech/Pfizer vaccine from the market or seek an injunction against future sales due to the life-saving role it plays in the pandemic. The BioNTech/Pfizer vaccine is sold under the brand name Comirnaty.

 
velo 2022-08-26 18:21:16 

did moderna give you money for this promotion big grin

 
Scar 2022-08-26 18:49:20 

1990 - Dr. Katalin Karikó, a researcher at the University of Pennsylvania in the United States, spent over a decade studying RNA to unlock its potential for use in medicine.

1995- Dr. Pieter Cullis and Dr. Jeffery Wheeler, start using lipid nanoparticles in medicine - gene therapy drugs that use nucleic acids (like RNA). The lipid nanoparticles form a protective bubble around the medicine so that it can be delivered to cells safely and effectively.

2005 - Dr. Katalin Karikó and Dr. Drew Weissman publish scientific papers about ther breakthrough: They realized how to make synthetic RNA safe tp inject into cells. The big step forward for developing RNA-based medicines

2007 - [i]Dr. Derrick Rossi, a Canadian stem cell biologist, starts his lab at Harvard Medical School in 2007. He sets out to build on the work of Drs. Karikó and Weissman, as well as the work of stem cell researcher Dr. Shinya Yamanaka. In 2009, his lab uses mRNA to make adult cells function like embryonic stem cells. This big news leads to the creation of Moderna in 2010.
[/i]
2010- r. Pieter Cullis and his team begin working with Dr. Drew Weissman and Dr. Katalin Karikó on vaccines that could use mRNA + lipid nanoparticles. This leads to collaborations with BioNTech and Pfizer.

2014 - Dr. Kizzmekia Corbett, a researcher with the National Institutes of Health (NIH) in the United States, begins work on coronavirus biology and vaccine development.

The world had already seen two coronavirus outbreaks with Severe Acute Respiratory Syndrome (SARS) in 2003 and Middle East Respiratory Syndrome (MERS) in 2012. Dr. Corbett and colleagues study these coronaviruses, including the signature “spike protein” and the role it could play in vaccine development.

[b]This leads to collaborations between the NIH and Moderna.
[/b]

2020 -[i]Complete genetic sequence of novel coronavirus published and shared with scientists around the world.
[/i]

2020- [i]Originally focused on MERS, Dr. Corbett’s team (under the direction of Dr. Barney Graham at the NIH’s Vaccine Research Centre) and Moderna pivot quickly to develop a COVID-19 vaccine using mRNA.

Originally focused on Zika and influenza, Drs. Cullis, Weissman, and Karikó halt other projects to focus on SARS-CoV-2 and develop a COVID-19 vaccine using mRNA and lipid nanoparticles.[/i]


Karikó's and American immunologist Drew Weissman scientific research of RNA-mediated immune activation, resulted in the co-discovery of the nucleoside modifications to suppress the immunogenicity of RNA.[3][4][5] This was further contribution to the therapeutic use of mRNA.[6] Together with Weissman, she holds U.S. patents for the application of non-immunogenic, nucleoside-modified RNA. This technology has been licensed by BioNTech and Moderna to develop their protein replacement technologies but was also used for their COVID-19 vaccines

Now let the courts decide who did what first. I would bet NIH wins vs Moderna first.

 
Scar 2022-08-26 19:43:58 

The greed never stops big grin

Moderna Therapeutics teamed up with government researchers at the US National Institutes of Health (NIH) to swiftly produce one of the world’s first successful COVID-19 vaccines.
… patent dispute between them in a battle over whether NIH researchers were unfairly left off as co-inventors on a pivotal vaccine patent application.
Moderna … will make US$18B on the vaccine. As an inventor NIH can collect royalties … getting back some taxpayer money & license the patent to other competing vaccine makers for low- and middle-income countries like India etc.
Before the COVID-19 , NIH and Moderna collaborated on vaccines for other coronaviruses. The SARS-CoV-2 outbreak made them work together on the vaccine.
Their mRNA vaccine has a modified shape of SARS-CoV-2 spike protein … NIH says these were developed by researchers the NIA and other collaborators… published it with other coronavirus modifications.
… Moderna has filed several patent applications on its COVID-19 vaccine that name NIH investigators as co-inventors … some including one that claims the mRNA sequence does not... Moderna admitted that the NIH had submitted three researchers as co-inventors….
Moderna claims its researchers independently developed the mRNA sequence for the vaccine. NIH says they developed the sequence and shared it Moderna.
The patent is critical because it covers the main component …any claim on the active ingredient in a pharmaceutical product makes it difficult for competitors.
Individuals, universities, government agencies and company laboratories often assign patent rights big institutions …. it can be difficult to name an inventor on a collaborative patent ,,. patent rights ownership -yes, but not really who will be an inventor.
The US government often funds early-stage research, and gives it to industry to manage intellectual property after invention. … the government has generally considered the potential benefit to taxpayers as the main reward for funding early research.
…the government has become more assertive about intellectual property, particularly if by doing so it could rein in the prices of prescription drugs. … the NIH’s outcry over its exclusion from the Moderna patent, suggests the government is taking more active stance on intellectual property
Moderna has said that it offered the NIH co-ownership of the patent in September, and that the agency could then license the patent “as they see fit”. But this is different from inventor status:
The NIH … lawsuit will argue in court that Moderna inappropriately left out NIH researchers. If dcided the NIH is correct, and omission was unintentional the patent can be corrected. If the court finds Moderna knowingly deceived the patent office about NIH’s contribution, the patent would no longer be valid.

 
Scar 2022-08-26 19:50:02 

In reply to velo He may have stocks. Mine is in Pfizer since 1990 before COVID

big grin

To be fair dem not claiming they inveny the process cause they didnt. They claiming Pfizer used an active ingredient which is theirs that is vital to the process but the BionTech peeps who first got the mRNA breakthrough were getting theirs working on the Zica etc. vaccines before Moderna was formed in 2010 big grin

 
Barry 2022-08-26 21:48:10 

In reply to velo
You mean if I own shares in moderna? The issue is intellectual property . . .

cool

 
Barry 2022-08-26 21:54:43 

In reply to Scar
You do know you can patent a process? China couldn't even do it . . . Also Moderna learnt to stabilize the MRNA using lipid based products

Link Text

Intellectual Property
The following are protected by patents in the United States and in foreign jurisdictions for Moderna Inc.

Spikevax™ (mRNA-1273 COVID-19 VACCINE)

US 10,898,574

US 10,703,789

US 10,702,600

US 10,577,403

US 10,442,756

US 10,266,485

US 10,064,959

US 9,868,692


Goes back to before 2010

Abstract
Background

mRNAs are highly versatile, non-toxic molecules that are easy to produce and store, which can allow transient protein expression in all cell types. The safety aspects of mRNA-based treatments in gene therapy make this molecule one of the most promising active components of therapeutic or prophylactic methods. The use of mRNA as strategy for the stimulation of the immune system has been used mainly in current strategies for the cancer treatment but until now no one tested this molecule as vaccine for infectious disease.
Results

We produce messenger RNA of Hsp65 protein from Mycobacterium leprae and show that vaccination of mice with a single dose of 10 μg of naked mRNA-Hsp65 through intranasal route was able to induce protection against subsequent challenge with virulent strain of Mycobacterium tuberculosis. Moreover it was shown that this immunization was associated with specific production of IL-10 and TNF-alpha in spleen. In order to determine if antigen presenting cells (APCs) present in the lung are capable of capture the mRNA, labeled mRNA-Hsp65 was administered by intranasal route and lung APCs were analyzed by flow cytometry. These experiments showed that after 30 minutes until 8 hours the populations of CD11c+, CD11b+ and CD19+ cells were able to capture the mRNA. We also demonstrated in vitro that mRNA-Hsp65 leads nitric oxide (NO) production through Toll-like receptor 7 (TLR7).
Conclusions

Taken together, our results showed a novel and efficient strategy to control experimental tuberculosis, besides opening novel perspectives for the use of mRNA in vaccines against infectious diseases and clarifying the mechanisms involved in the disease protection we noticed as well.